ArticleESC heart failure2025
Diagnostic value of computed tomography-based muscle quality and metabolic signatures in heart failure with sarcopenia.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A feasibility study of computed tomography muscle phenotyping for physiotherapy selection in peripheral arterial disease.Journal of vascular surgery cases and innovative techniques · 2026Article
- Exerkine dysregulation links visceral adiposity to skeletal muscle impairment in end-stage heart failure with reduced ejection fraction: proteomic evidence for a cardio-adipose-muscle axis.Cardiovascular diabetology · 2026Article
- Diagnostic value of computed tomography-based muscle quality and metabolic signatures in heart failure with sarcopenia.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimsSarcopenia is a major comorbidity in heart failure (HF) patients, but its comprehensive evaluation remains challenging due to resource limitations. Computed tomography (CT) imaging allows opportunistic assessment of both muscle quantity and quality; however, its diagnostic utility and relationships with physical performance and underlying metabolic alterations remain unclear. We investigated the diagnostic utility of single-slice abdominal CT for sarcopenia assessment and explored its association with plasma amino acid profiles in HF patients. METHODS AND
resultsWe retrospectively analysed 212 HF patients (73 ± 13 years old; 41% females) who underwent dual-energy X-ray absorptiometry (DXA), abdominal CT imaging, and amino acid profiling, of whom 186 had complete sarcopenia assessment. Sarcopenia was diagnosed based on the Asian Working Group for Sarcopenia 2019 criteria using DXA-measured appendicular skeletal muscle mass index and grip strength, with severe sarcopenia additionally requiring low Short Physical Performance Battery scores. CT-measured skeletal muscle area index (SMI) at the lumbar vertebral level combined with grip strength showed high diagnostic accuracy for sarcopenia [area under the receiver operating characteristic curve (AUC): 0.96 for males, 0.88 for females], with optimal cut-off values of 54 cm
conclusionsSingle-slice abdominal CT provides accurate sarcopenia diagnosis in HF patients with reduced muscle strength, with muscle quality rather than quantity determining physical performance. Specific amino acid profiles associated with muscle quality changes suggest potential therapeutic targets for preventing sarcopenia progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.